Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

arges - 5,367 - 5,367

Net loss, non-GAAP $(4,294) $(39,045) $(36,193) $(94,101)

Basic and diluted net loss

per share, as reported $(0.07) $(0.97) $(0.60) $(1.91)

Adjustments $- $0.31 $- $0.31

Basic and diluted net loss

per share, non-GAAP** $(0.07) $(0.66) $(0.60) $(1.59)

Shares used in computing

basic and diluted net loss

per share 60,856 59,223 60,706 59,089

**The values shown above are exact; totals may not appear to sum due to rounding

CONSOLIDATED BALANCE SHEET DATA

(In Thousands)

(Unaudited)

June 30, 2008 December 31, 2007

Assets:

Cash, cash equivalents, and

marketable securities $272,313 $174,245

Other current assets 40,874 41,825

Total current assets 313,187 216,070

Property and equipment, net 16,639 19,131

Other assets 20,815 23,635

Total assets $350,641 $258,836

Liabilities and stockholders' deficit:

Current liabilities $46,534 $39,183

Convertible subordinated notes 346,500 399,500

Deferred revenue 159,805 -

Other long-term obligations 4,675 5,551

Stockholders' deficit (206,873) (185,398)

Total liabilities and stockholders'

deficit $350,641 $258,836


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... for Reproductive Medicine (ASRM), a leading professional organization committed to ... new role as treasurer, Dr. Hill also fills a seat ... furthering the mission of ASRM. , Dr. Hill has ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... 2011 Ingenuity® Systems, a leading provider of ... Medical Center, jointly announced a scientific collaboration using ... As part of the collaboration, Erasmus researchers ... the most impactful biological insights from their NGS ...
... 2011 Accuray Incorporated (Nasdaq: ARAY ), a ... it will report results for its second quarter of fiscal ... after the market closes. A conference call to ... ET and will be hosted by Euan S. Thomson, Ph.D., ...
... the world,s leading provider of medical image analysis services ... Dr. Peter Milner has joined SYNARC to expand and ... solutions for the clinical trial setting. Dr. ... brings over 25 years of experience in drug development ...
Cached Biology Technology:Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2SYNARC Engages Dr. Peter Milner for Cardiac Imaging Services and Solutions 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... rise, some species of corals are likely to succeed at ... on April 12 in the Cell Press journal Current ... effects on corals. "The good news is that, rather ... change by changing the mix of coral species as the ...
... fit frogs have faster-changing genomes, says a new study ... Stretches of DNA accumulate changes over time, but the ... between species, said author Juan C. Santos of the ... In the past, biologists trying to explain why some ...
... cause hearing damage to Sailors and Marines on flight ... funding a new project to help reduce jet noise, ... into two categories: noise exposure on the flight deck ... said Dr. Brenda Henderson, deputy manager for the Jet ...
Cached Biology News:Under climate change, winners and losers on the coral reef 2Athletic frogs have faster-changing genomes 2ONR taps research teams to help reduce jet noise 2
From formula-fed bovine calves Sterile, Cell culture tested...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... may be carried out using this high ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied automatic sample injector has ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
Biology Products: